Growth-hormone replacement
1Confirmed deficiency; not a general wellness indication.
HormonalProtein
HGH / somatropin
Recombinant human growth hormone
Studied forGrowth-hormone deficiency1
Somatropin is FDA approved for specified indications; not an approved general anti-aging treatment.
What does it do?
Somatropin replaces growth hormone in specific diagnosed conditions. Evidence for treating deficiency differs from wellness or athletic use in healthy adults.
Approved & studied uses
Community uses Reported, unvalidated
Approved indications
13Product-specific pediatric growth conditions, adult deficiency and HIV wasting.
Wellness, athletic use and injury
13Unapproved goals; lean-mass changes do not establish performance benefit.
Body composition
13Fat/lean-mass changes are context-dependent; long-term risks matter.
Reasons people report using it; these do not establish benefit.13
Evidence limits
View research →Research-market product identity, purity and formulation cannot be established from a publication.1
3 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Key safety information
All risks →Fluid retention and glucose effects
Edema, joint symptoms and impaired glucose tolerance may occur.1
Somatropin is FDA approved for specified indications; not an approved general anti-aging treatment.
Molecular information
Amino-acid sequence
An exact sequence has not been verified for this formulation.
Length191 residues
Molecular weight · Da22,124 Da
Formula, sequence notation & identity
Molecular formulaNot stated in the checked label1
Recombinant human growth hormone
Unmodified somatropin; long-acting GH products are different entities.
Pep-Pedia identity details
191 amino acids · 22,124 Da (22 kDa)
191 amino acid single-chain protein with 4 cysteine residues forming 2 intrachain disulfide bonds. Identical to endogenous pituitary-derived hGHReference description; checked chemical identity above takes precedence when available.13
Pharmacokinetics
How long does it stay in the body?
Human data
Reported half-life3 hours (Genotropin SC)1
Route / formulationSubcutaneous
50%of reference level
Illustrative model using reported human data.
About 3% remaining after 15 h
Five half-lives in this simplified model. This is not a prediction of when effects stop.
Evidence and model details
Label mean estimate for Genotropin; intravenous kinetics and long-acting GH products differ.
Population: Adults with GH deficiency
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
Replacement has a defined population
Genotropin treats diagnosed adult GH deficiency and specified pediatric growth disorders.1
Newer long-acting research is formulation-specific
foresiGHt included daily somatropin but primarily evaluated lonapegsomatropin versus placebo. Long-acting product doses and kinetics cannot be transferred to ordinary somatropin.2
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Duration of use
The source hides 3 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Age range
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
The source hides 9 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Effectiveness
The source hides 17 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
The source hides 15 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Dosage frequency
Number of responses to this question: not disclosed.
Would recommend
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
How discovered
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Source & limitations
The source displays “1271 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
Protocols
Doses & schedules
Compare purpose, amount, route, frequency, and duration.
Source corrections
Source interaction labels are not instructions to add hormones; pregnancy/lactation safety and healthy-person long-term benefit remain uncertain.
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQSubcutaneous | Label example: approximately 0.2 mg/day initially | Daily | Adult GH replacementProduct label | Individually monitored | 1 |
Population Adults with confirmed GH deficiency Context Non-weight-based option; clinician titration follows response and age-adjusted IGF-1. | |||||
| SubQ | 0.15-0.3 mg/day (0.5-1 IU)Starting dose | Once daily | Medical GHD Replacement (Starting)Reference report | 3-6 months minimum for body composition; can be used long-term under medical supervision | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source interaction labels are not instructions to add hormones; pregnancy/lactation safety and healthy-person long-term benefit remain uncertain. Source tabs Injectable | |||||
| SubQ | 0.4-0.8 mg/day (1.2-2.4 IU) | Once daily | Medical GHD Replacement (Maintenance)Reference report | 3-6 months minimum for body composition; can be used long-term under medical supervision | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source interaction labels are not instructions to add hormones; pregnancy/lactation safety and healthy-person long-term benefit remain uncertain. Source tabs Injectable | |||||
| SubQ | 1-2 IU/day (0.33-0.67 mg) | Once daily | Anti-Aging / Wellness (Conservative)Reference report | 3-6 months minimum for body composition; can be used long-term under medical supervision | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source interaction labels are not instructions to add hormones; pregnancy/lactation safety and healthy-person long-term benefit remain uncertain. Source tabs Injectable | |||||
| SubQ | 2-4 IU/day (0.67-1.33 mg) | Once or twice daily | Body Recomposition (Moderate)Reference report | 3-6 months minimum for body composition; can be used long-term under medical supervision | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source interaction labels are not instructions to add hormones; pregnancy/lactation safety and healthy-person long-term benefit remain uncertain. Source tabs Injectable | |||||
| SubQ | 4-8 IU/day (1.33-2.67 mg) | Split twice daily | Performance (Higher - More Risk)Reference report | 3-6 months minimum for body composition; can be used long-term under medical supervision | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source interaction labels are not instructions to add hormones; pregnancy/lactation safety and healthy-person long-term benefit remain uncertain. Source tabs Injectable | |||||
| SubQ | 2-4 IU | Morning on empty stomach | Fasted Morning ProtocolReference report | 3-6 months minimum for body composition; can be used long-term under medical supervision | 13 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source interaction labels are not instructions to add hormones; pregnancy/lactation safety and healthy-person long-term benefit remain uncertain. Source tabs Injectable | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- 3-6 months minimum for body composition; can be used long-term under medical supervision
- Break
- Some protocols cycle 5 days on/2 days off or take periodic breaks; medical replacement is typically continuous
Reported timing
Morning on empty stomach for fat loss; evening mimics natural secretion; split doses at higher amounts
Side effects & safety
Fluid retention and glucose effects
Edema, joint symptoms and impaired glucose tolerance may occur.
1Contraindications
Includes active malignancy and acute critical illness.
1Contraindications
Active malignancy, acute critical illness and growth promotion after epiphyseal closure.
Metabolic/endocrine effects
Insulin resistance, edema, carpal tunnel, joint pain; thyroid/adrenal deficiencies can emerge.
Urgent symptoms
Severe headache/vision change, allergy, marked edema, hyperglycemia, masses or progressive hand weakness.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
11 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
IGF-1 / IGF-1 LR3
Caution reportedExcess growth signaling.13
Reference report · Evidence context: Synergistic but cautionThyroid hormones
Caution reportedThyroid needs can change.13
Reference report · Evidence context: Monitor requiredMetformin
Caution reportedGlucose/IGF-1 effects.13
Reference report · Pep-Pedia label: Monitor CombinationInsulin, glucocorticoids and oral estrogen
Label warningReplacement requirements or glucose-lowering doses may need clinical reassessment.1
Research contextInsulin
Unverified pairingReduced insulin sensitivity.13
Reference report · Evidence context: Complex interactionCJC-1295
Unverified pairingSource claim; redundant stimulation possible.13
Reference report · Pep-Pedia label: SynergisticIpamorelin
Unverified pairingCombination safety unestablished.13
Reference report · Pep-Pedia label: SynergisticGHRP-6 / GHRP-2
Unverified pairingCombination safety unestablished.13
Reference report · Pep-Pedia label: SynergisticCortisol/hydrocortisone
Unverified pairingAdrenal replacement needs review.13
Reference report · Evidence context: Important interactionTestosterone
Unverified pairingDiagnosis-specific replacement.13
Reference report · Pep-Pedia label: SynergisticSemaglutide/tirzepatide
Unverified pairingWeight-management pairing unvalidated here.13
Reference report · Evidence context: ComplementaryNo matching interactions. Try another name or filter.
Reconstitution
Use the matched two-chamber cartridge and supplied diluent; research powders are not interchangeable.1
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
Pep-Pedia describes an example for dry growth-hormone material; marketed products have different presentations.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- Example: 10 IU in 1 mL gives 1 IU per 0.1 mL. · Reported refrigerated interval: 14–28 days at 2–8°C, depending on product.
The source describes gentle mixing and avoiding vigorous shaking.
HGH IU are biological activity units, not U-100 syringe units. Exact product instructions govern the diluent and shelf life.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceWhite lyophilized powder/cakeReported appearanceCrystal clear reconstituted solutionReported appearanceVacuum intact in sealed vialReported appearancePharmaceutical grade with COAReported variationGeneric/underground lab productsReported concernCloudy, discolored, or particles visibleReported concernPowder appears melted or stuck to vial
13Available forms
Genotropin 5 mg / 12 mg cartridges
Two-chamber prescription delivery system; preparation follows its own device instructions.1
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Checked product labels
These limits apply only to the named product and its specified diluent.
Genotropin 5 mg / 12 mg cartridges
14Store protected from light; do not freeze. Applies to these cartridges and their supplied formulation.
Genotropin MiniQuick
14Single-use product; discard after use. This is not the same storage limit as the multi-dose cartridge.
Reconstituted research vials
Refrigerated lifetime not established
The checked sources do not establish how long this research preparation remains stable and sterile after mixing.13
Full storage notes from Pep-Pedia
13Lyophilized: refrigerate 2-8°C; Reconstituted: refrigerate, use within 14-28 days; Never freeze
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Research findings
Human trialsSource context
Source interaction labels are not instructions to add hormones; pregnancy/lactation safety and healthy-person long-term benefit remain uncertain.
Compound identity & other names
Somatropin is replacement therapy for specified growth-hormone deficiency indications. Findings in deficient patients do not establish anti-aging or performance benefits in people with normal GH function.
Other names: HGH (Somatropin)
Somatropin is FDA approved for specified indications; not an approved general anti-aging treatment.
How it may work
GH-receptor/JAK–STAT signaling plus IGF-1 production affects growth, lipid and protein metabolism.13
Replacement has a defined population
Genotropin treats diagnosed adult GH deficiency and specified pediatric growth disorders.
1Newer long-acting research is formulation-specific
foresiGHt included daily somatropin but primarily evaluated lonapegsomatropin versus placebo. Long-acting product doses and kinetics cannot be transferred to ordinary somatropin.
2Research areas and evidence gaps
Growth-hormone replacement. Confirmed deficiency; not a general wellness indication.1
- Research-market product identity, purity and formulation cannot be established from a publication.
Community reports Unvalidated
Wellness discussions as described by Pep-Pedia.3
No representative survey, independently verified products, or controlled outcomes.
Search coverage and review status
The targeted check identified relevant additional literature or current regulatory information; checked findings are separated from retained bibliography-only references.
- Checked
- 2026-10-12
- Search
- somatropin 2025 2026 randomized trial adults growth hormone deficiency site:pubmed.ncbi.nlm.nih.gov
- Catalog
- Pep-Pedia ↗ · 9 listed references retained
- Targeted search, not an exhaustive systematic review.
- Bibliography-only entries are retained for traceability and are not treated as verified findings.
AI-prepared summaries. Independent medical editorial review is pending.
References
Original sources and review status. Open a reference to read its summary.
1Genotropin US prescribing information, revised July 2026Primary source checked
AI-PREPARED SUMMARY
Label covers diagnosed GH deficiency and selected pediatric indications, product-specific cartridges, contraindications and monitoring.
Replacement has a defined population
Genotropin treats diagnosed adult GH deficiency and specified pediatric growth disorders.
Additional research · Checked 2026-10-12
2foresiGHt: lonapegsomatropin trial with daily somatropin comparatorAbstract checked
AI-PREPARED SUMMARY
2026 trial included a daily somatropin comparator; the reported placebo-controlled efficacy estimates concern the long-acting prodrug.
Newer long-acting research is formulation-specific
foresiGHt included daily somatropin but primarily evaluated lonapegsomatropin versus placebo. Long-acting product doses and kinetics cannot be transferred to ordinary somatropin.
Additional research · Checked 2026-10-12
3Pep-Pedia: HGH / somatropin — community referenceCommunity source checked
AI-PREPARED SUMMARY
Accessed October 12, 2026. Secondary descriptions and bibliography; community schedules are unvalidated reports, not recommendations.
4KIMS Long-Term Safety Study (2022)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: An observational GHD registry reported cancer incidence near the population rate (SIR 0.92); selection and surveillance limit causal safety conclusions.
Reported population / model
Worldwide observational study
Reported study details
15,809 patients · Mean 5.3 years follow-up · Adult GHD
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
5Effects on Morbidity - Systematic Review (2014)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Trials improved cardiovascular surrogates and bone metabolism; reduced cardiovascular events or fractures were not established by those endpoints.
Reported population / model
Systematic review of RCTs
Reported study details
Cardiovascular and bone metabolism endpoints
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6Adult GHD Clinical Syndrome Characterization (2011)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source characterizes adult GH deficiency through exercise, wellbeing, body-fat, lipid and bone abnormalities; this is disease context rather than a trial.
Reported population / model
Multiple studies
Reported study details
Clinical manifestations and treatment response
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7GH-Thyroid Hormone Interaction Study (2011)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: GH replacement reportedly exposed central hypothyroidism in some hypopituitary patients through thyroid-hormone conversion changes.
Reported population / model
Hypopituitary patients
Reported study details
T4/T3 conversion effects · Hypothyroidism unmasking
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Long-term Efficacy and Safety in Adult GHD (2005)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The review reports body-composition, bone, lipid and quality-of-life improvements in adults with established GH deficiency.
Reported population / model
Systematic review
Reported study details
Body composition, bone density, quality of life outcomes
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
9GENOTROPIN Clinical Trials Program (1990s-2000s)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Six placebo-controlled studies of 172 GH-deficient adults supported body-composition benefits of somatropin replacement.
Reported population / model
6 randomized clinical trials
Reported study details
172 adult GHD patients · Placebo-controlled
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
10Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a meta-analysis of blinded, randomized, placebo-controlled trialsLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
11Effects of Growth Hormone on Glucose and Fat Metabolism in Human SubjectsLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
12Adult Growth Hormone Deficiency - Benefits, Side Effects, and Risks of Growth Hormone ReplacementLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
13Pep-Pedia: HGH / somatropin — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12
14Genotropin label: cartridge and MiniQuick storagePrimary source checked
AI-PREPARED SUMMARY
After mixing, the labeled 5 mg and 12 mg cartridges can be refrigerated for up to 28 days. MiniQuick is single-use, with up to 24 hours of refrigeration before use.